NO20052009L - Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome - Google Patents

Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Info

Publication number
NO20052009L
NO20052009L NO20052009A NO20052009A NO20052009L NO 20052009 L NO20052009 L NO 20052009L NO 20052009 A NO20052009 A NO 20052009A NO 20052009 A NO20052009 A NO 20052009A NO 20052009 L NO20052009 L NO 20052009L
Authority
NO
Norway
Prior art keywords
treatment
myelodysplastic syndrome
acute leukemia
combination therapy
pharmaceutical combinations
Prior art date
Application number
NO20052009A
Other languages
Norwegian (no)
Other versions
NO20052009D0 (en
Inventor
Jay Marshall Feingold
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20052009D0 publication Critical patent/NO20052009D0/en
Publication of NO20052009L publication Critical patent/NO20052009L/en

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Abstract

Det beskrives fremgangsmåter for behandling og farmasøytiske kombinasjoner for behandlingen av akutt leukemi, så som akutt myelogen leukemi og myelodysplastisk syndrom. Fremgangsmåtene og de farmasøytiske kombinasjonene benytter et anti-CD33 cytotoksisk konjugat i kombinasjon med minst én forbindelse valgt fra gruppen bestående av et antracyklin og en pyrimidin- eller purin-nukleosidanalog. Foretrukne fremgangsmåter for behandling og farmasøytiske kombinasjoner benytter gemtuzumab ozogamicin, daunorubicin og cytarabin.Methods of treatment and pharmaceutical combinations for the treatment of acute leukemia, such as acute myelogenous leukemia and myelodysplastic syndrome, are described. The methods and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analogue. Preferred methods of treatment and pharmaceutical combinations utilize gemtuzumab ozogamicin, daunorubicin and cytarabine.

NO20052009A 2002-11-06 2005-04-25 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome NO20052009L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
NO20052009D0 NO20052009D0 (en) 2005-04-25
NO20052009L true NO20052009L (en) 2005-06-27

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052009A NO20052009L (en) 2002-11-06 2005-04-25 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Country Status (10)

Country Link
EP (1) EP1575582A4 (en)
JP (1) JP2006508119A (en)
CN (1) CN1720044A (en)
AU (2) AU2002348178A1 (en)
BR (1) BR0215935A (en)
CA (1) CA2504611A1 (en)
CR (1) CR7804A (en)
MX (1) MXPA05004711A (en)
NO (1) NO20052009L (en)
WO (1) WO2004043461A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977320B2 (en) 2004-10-29 2011-07-12 The Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
CA2614321A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
ATE521366T1 (en) * 2006-05-27 2011-09-15 Faulstich Heinz Dr APPLICATION OF AMATOXIN CONJUGATES AND PHALLOTOXIN CONJUGATES WITH MACROMOLECLES FOR CANCER THERAPY AND THERAPY OF INFLAMMATION
CN1994293A (en) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 Application of oridonin in medicine preparation
JP2010509234A (en) * 2006-11-02 2010-03-25 シアトル ジェネティックス， インコーポレイテッド Methods for treating neoplastic diseases, autoimmune diseases and inflammatory diseases
US20100303895A1 (en) * 2007-02-16 2010-12-02 Arthur Louie Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
JP5592793B2 (en) 2008-08-29 2014-09-17 学校法人北里研究所 Method for detecting drug effect of DNA methylation inhibitor
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
EP3463463A4 (en) * 2016-06-03 2020-01-15 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
EP3469001A4 (en) 2016-06-09 2020-05-06 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
BR112019026959A2 (en) * 2017-06-22 2020-07-07 Les Laboratoires Servier combination of an mcl-1 inhibitor and standard treatment for haematological cancers, their uses and pharmaceutical compositions
JP7305613B2 (en) * 2017-07-09 2023-07-10 バイオサイト リミテッド Combination cancer therapy
SG11202107906UA (en) * 2019-01-28 2021-08-30 Univ Texas Metal chelator combination therapy for the treatment of cancer
CN110123825B (en) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 Pharmaceutical composition containing demethoxydaunorubicin
JP2023548111A (en) * 2020-10-27 2023-11-15 ブイオーアール バイオファーマ インコーポレーテッド Compositions and methods for treating hematopoietic malignancies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
DK1309627T3 (en) * 2000-08-08 2009-12-21 Immunomedics Inc Immunotherapy for chronic myelocytic leukemia with nude anti-NCA-90 antibody

Also Published As

Publication number Publication date
EP1575582A1 (en) 2005-09-21
WO2004043461A1 (en) 2004-05-27
AU2010201113A1 (en) 2010-04-15
NO20052009D0 (en) 2005-04-25
AU2002348178A1 (en) 2004-06-03
JP2006508119A (en) 2006-03-09
CR7804A (en) 2008-10-29
BR0215935A (en) 2005-08-09
MXPA05004711A (en) 2005-08-03
EP1575582A4 (en) 2009-03-11
CA2504611A1 (en) 2004-05-27
CN1720044A (en) 2006-01-11

Similar Documents

Publication Publication Date Title
NO20052009L (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
WO2007022073A3 (en) Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
WO2022047065A3 (en) Compounds and methods for treatment of viral infections
CY1113012T1 (en) LIPOSOMIC PHARMACEUTICAL FORMS OF CARBONIC CYLINDER AND CYTIDINE ANALOG
AP2005003211A0 (en) 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
HRP20070383T3 (en) Rapamycin carbohydrate derivatives
WO2003099346A3 (en) Compositions and methods for coating medical implants
DE69230140T2 (en) ANTIVIRAL NUCLEOSIDE COMBINATION
BRPI0507675A (en) 2'-c-methyl nucleoside derivatives
TW200510445A (en) Modified fluorinated nucleoside analogues
BRPI0503981A (en) low calorie sugar substitute with water-insoluble bulking agent
MX2009012155A (en) A synergistic pharmaceutical combination for the treatment of cancer.
NO20061402L (en) Anti-tumor formulations comprising defibrotide alone or in combination with other antitumor agents
WO2004028475A3 (en) Glycosylceramide analogues
PT1368041E (en) AQUOSA COMPOSITION OF ANFOTERICINE
WO2008104893A3 (en) Nucleoside derivatives useful for the treatment or prevention of viral infections and methods of use thereof
HUP0300219A2 (en) Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
WO2005000204A3 (en) Pancreatic cancer treatment
DK1079840T3 (en) Synergistic preparation of inulin and an anticancer drug for use in the treatment of cancer
UA83204C2 (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
DE602006013953D1 (en) 9A-CARBAMOYL-Y-AMINOPROPYL AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL AZALIDES WITH ANTIMALARIA ACTIVITY
HUP0402401A2 (en) Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the treatment of cancer
BR0104352A (en) Taxanes substituted by c10 carbamoyloxy as antitumor agents
ZA200405345B (en) Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins.
TW202417008A (en) 1'-cyano nucleoside analogs and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application